5 Thought Leaders from the ASCO 2020 Meetings You Should Know

5 Thought Leaders from the ASCO 2020 Meetings You Should Know

Josh Pirtle

February 9, 2021

No items found.

Dr. Julia R. White, MD

Discussant Julia R. White, MD, of The Ohio State University Comprehensive Cancer Center, said that there currently exists an ongoing debate about the optimal treatment of patients with de novo metastatic breast cancer. Dr. White noted that the study by Dr. Khan et al is now the fourth trial that addresses LRT for the primary tumor in de novo metastatic breast cancer.

ASCO 2020 Article here


Dr. Sham Mailankody

During the ASCO20 Virtual Scientific Program (Abstract 8504) Sham Mailankody, MBBS, of Memorial Sloan Kettering Cancer Center, presented an analysis of the ongoing, open-label phase I/II EVOLVE trial. Patients with relapsed/refractory MM were enrolled in this study if they had received at least three prior anti-myeloma treatment regimens, including an autologous stem cell transplant, an immunomodulatory agent, and an anti-CD38 monoclonal antibody in combination with another therapy or as monotherapy. Only patients with disease refractory to their last line of therapy before they entered the study were eligible for inclusion.

ASCO 2020 Article here                                              

Dr. Jeremy L. Warner

Jeremy L. Warner, MD, of Vanderbilt University Medical Center, presented the initial results of the registry study of the COVID-19 and Cancer Consortium (CCC19; Abstract LBA110). The study began on March 15, 2020, with the objective to rapidly collect and disseminate prospective, granular, uniformly organized data from patients with cancer who have been diagnosed with COVID-19. Cases from the first 30 days of the registry (March 17-April 16, 2020) were analyzed. The primary outcome was 30-day all-cause

ASCO 2020 article here                                            

Dr. Neal D. Shore

Relugolix is a novel oral gonadotropin-releasing hormone antagonist that has the potential to become a new standard for ADT in advanced prostate cancer,” concluded Neal D. Shore, MD, FACS, of the Carolina Urologic Research Center, who presented the HERO results during the ASCO20 Virtual Scientific Program.

ASCO 2020 Article here                                              

Dr. Vivek Subbiah

During the ASCO20 Virtual Scientific Program, Vivek Subbiah, MD, of The University of Texas MD Anderson Cancer Center, presented results from the ARROW basket cohort of patients with other RET fusion–positive solid tumors; these patients had been treated with 400 mg of oral pralsetinib once daily. The primary endpoints were the centrally reviewed overall response rate (ORR; per RECIST version 1.1 criteria) and safety.

ASCO 2020 Article here                                              

Trusted by the top Medical Affairs companies in the world, H1 has the most accurate and most updated data in healthcare today.

Request Demo

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.